The study reviewed 93 patients with suspected choledocholithiasis who underwent EUS. Of these patients, 52.7 percent were considered to have intermediate likelihood of CBD stones and 47.3 percent were considered to have a high likelihood.
EUS had a sensitivity of 100 percent and specificity of 80 percent. Of the intermediate likelihood group, CBD stones were detected in 22.44 percent of patients. Of the high likelihood group, CBD stones were detected in 38.63 percent of patients.
The researchers concluded that EUS is an accurate diagnostic tool and may prevent unnecessary use of ERCP, according to the report.
More articles on gastroenterology:
6 things to know about colonoscopy cost & what a reimbursement cut would mean
32 statistics on ASC accounts receivable
M*Modal releases outpatient medical coding services
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.